Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Leases (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of Operating Leases data on record, last reported at $1.1 million in Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.1 million, changed N/A, while the annual FY2024 figure was $1.2 million, 597.02% up from the prior year.
  • Operating Leases reached $1.1 million in Q3 2025 per DNTH's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $31.6 million in Q2 2022 and bottomed at $30000.0 in Q2 2024.
  • Average Operating Leases over 4 years is $7.8 million, with a median of $1.1 million recorded in 2025.
  • Peak YoY movement for Operating Leases: crashed 99.05% in 2023, then skyrocketed 3630.0% in 2025.
  • A 4-year view of Operating Leases shows it stood at $438000.0 in 2022, then tumbled by 61.64% to $168000.0 in 2023, then surged by 597.02% to $1.2 million in 2024, then dropped by 8.8% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $1.1 million in Q3 2025, $1.1 million in Q2 2025, and $1.2 million in Q1 2025.